H.C. Wainwright Thinks Global Blood Therapeutics’ Stock is Going to Recover


Global Blood Therapeutics (GBT) received a Buy rating and a $75.00 price target from H.C. Wainwright analyst Andrew Fein today. The company’s shares closed last Monday at $42.70, close to its 52-week low of $36.49.

According to TipRanks.com, Fein is a 5-star analyst with an average return of 17.5% and a 55.1% success rate. Fein covers the Healthcare sector, focusing on stocks such as Deciphera Pharmaceuticals, Zentalis Pharmaceuticals, and KalVista Pharmaceuticals.

Currently, the analyst consensus on Global Blood Therapeutics is a Moderate Buy with an average price target of $90.58, which is an 119.4% upside from current levels. In a report issued on December 3, RBC Capital also initiated coverage with a Buy rating on the stock with a $75.00 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $87.54 and a one-year low of $36.49. Currently, Global Blood Therapeutics has an average volume of 1.4M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. It also provides oral medicines for sickle cell diseases. The company was founded by Matthew P. Jacobson, Andrej Sali, Jack Taunton, Charles J. Homcy, Craig D. Muir and David R. Phillips in February 2011 and is headquartered in South San Francisco, CA.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts